A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

Conditions:   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma Intervention:   Drug: YY-20394 Sponsor:   Shanghai YingLi Pharmaceutical Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials